[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-357257-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-357257-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-machine-learning-framework-combining-cfdna-fragmentomics-and-serum-biomarkers-for-early-ovarian-cancer-detection","A machine learning framework combining cfDNA fragmentomics and serum biomarkers for early ovarian cancer detection","","Ovarian cancer is a leading cause of cancer-related mortality in women, driven in part by limited effectiveness of early detection. This study develops a liquid biopsy assay that integrates cell-free DNA (cfDNA) fragmentomic features with serum biomarkers for sensitive diagnosis. Plasma cfDNA from training, independent validation, and an external validation cohort was sequenced to extract copy number variation and fragment-related features, which were combined via stacked machine learning with CA125 and HE4.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-machine-learning-framework-combining-cfdna-fragmentomics-and-serum-biomarkers-for-early-ovarian-cancer-detection/357257/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-machine-learning-framework-combining-cfdna-fragmentomics-and-serum-biomarkers-for-early-ovarian-cancer-detection/357257.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What goal does the proposed model serve in ovarian cancer care?","Question",{"text":63,"@type":64},"It aims to enable sensitive early ovarian cancer detection by combining cfDNA fragmentomic features with serum biomarkers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are cfDNA features and serum biomarkers used in the diagnostic pipeline?",{"text":68,"@type":64},"The approach extracts fragmentomic features from low-coverage whole-genome sequencing, integrates them with a stacked machine-learning model, and then combines the result with CA125 and HE4 to form the final diagnostic model.",{"name":70,"@type":61,"acceptedAnswer":71},"What diagnostic performance was reported in validation cohorts?",{"text":72,"@type":64},"In the independent validation cohort, the combined model reached an AUC of 0.968 with 85.7% sensitivity and 96.0% specificity, and in early-stage disease it achieved an AUC of 0.938 with 72.2% sensitivity at 96% specificity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},357257,1790194125,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},4398046744996,"Weng et al. Cell Communication and Signaling (2026) 24:365  \n[https://doi.org/10.1186/s12964-026-02908-x](https://doi.org/10.1186/s12964-026-02908-x)  \nCell Communication and Signaling  \nRESEARCH Open Access  \nA machine learning framework combining  cfDNA fragmentomics and serum biomarkers for early ovarian cancer detection  \nWanying Weng1†, Qunxian Rao2,3†, Song Wang4†, Ruilin Lei2,3, Ruixin Li2,3, Lin Lin2,3, Yunyun Liu5, Dongqin Zhu4, Hua Bao4, Weijian Zhang6, Jihong Wei6, Xingrong Qing6, Xiaohong Ruan6*, Guocai Xu2,3* and Bingzhong Zhang2,3*  \nAbstract  \nBackground Ovarian cancer (OC) is a leading cause of cancer-related mortality in women, largely due to the lack of effective strategies for early detection. Here, we aimed to develop a liquid biopsy assay integrating cell-free DNA (cfDNA) fragmentomic features with serum biomarkers for sensitive OC detection.  \nMethods Plasma cfDNA from training (n = 91) and independent validation (n = 46) cohorts comprising patients with OC, benign ovarian diseases, and healthy controls, underwent low-coverage whole-genome sequencing to extract copy number variation, fragment size distribution, and Neomer features. Fragmentomic features were first integrated using a stacked machine-learning model and subsequently combined with serum biomarkers CA125 and HE4 to construct the final diagnostic model. Model performance was evaluated in the overall cohort and stratified by disease stage, histological subtype, and tumor grade. An external validation cohort (n = 58) was further used to assess model generalizability.  \nResults The combined model integrating cfDNA fragmentomic features and serum biomarkers demonstrated superior diagnostic accuracy compared with all alternative approaches. In the independent validation cohort, the model achieved an AUC of 0.968 (95% CI: 0.896–0.996), with 85.7% sensitivity and 96.0% specificity. For early-stage OC (FIGO stage I and II), the model yielded an AUC of 0.938 (95% CI: 0 .864–0. 988), achieving 72. 2% sensitivity at a specificity of 96% . Robust performance was observed across histological subtypes (AUC: 0 .925–0. 991) and tumor grades (AUC: 0 .976–0. 977) . Stratified analyses further confirmed strong discrimination between OC and healthy controls (AUC: 0 . 995, 95% CI: 0 .980–1. 000) as well as benign ovarian diseases (AUC: 0 . 963, 95% CI: 0 .921–0. 993) . In the external validation cohort, the combined model maintained robust diagnostic performance, achieving an AUC of 0.962 (95% CI: 0 .898–0. 991), with 86. 2% sensitivity at 96% specificity.  \n†Wanying Weng, Qunxian Rao and Song Wang contributed equally to this work.  \n*Correspondence:  \nXiaohong Ruan [ruanxiaohong@jmszxyy.com.cn](ruanxiaohong@jmszxyy.com.cn)[ ](ruanxiaohong@jmszxyy.com.cn)Guocai Xu [xuguocai3@mail.sysu.edu.cn](xuguocai3@mail.sysu.edu.cn)[ ](xuguocai3@mail.sysu.edu.cn)Bingzhong Zhang [zhbzhong@mail.sysu.edu.cn](zhbzhong@mail.sysu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, vis","cbCaivNcu1OLFUW6","https://ap.wps.com/l/cbCaivNcu1OLFUW6","pdf",3547757,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n## Keywords\n## Background (context and rationale)","[{\"question\":\"What goal does the proposed model serve in ovarian cancer care?\",\"answer\":\"It aims to enable sensitive early ovarian cancer detection by combining cfDNA fragmentomic features with serum biomarkers.\"},{\"question\":\"How are cfDNA features and serum biomarkers used in the diagnostic pipeline?\",\"answer\":\"The approach extracts fragmentomic features from low-coverage whole-genome sequencing, integrates them with a stacked machine-learning model, and then combines the result with CA125 and HE4 to form the final diagnostic model.\"},{\"question\":\"What diagnostic performance was reported in validation cohorts?\",\"answer\":\"In the independent validation cohort, the combined model reached an AUC of 0.968 with 85.7% sensitivity and 96.0% specificity, and in early-stage disease it achieved an AUC of 0.938 with 72.2% sensitivity at 96% specificity.\"}]","A machine learning framework combining cfDNA fragmentomics and serum biomarkers for early ovarian cancer detection | PDF",1790129498,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe1c505d8257067751bb9b57822de4ba.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5dc49c5f05c6c6c4c77d193c789929c1.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68d3dae9f2602f99b9f684603aa8c380.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bca075b2176bf8fa4327b529c58d0ed.webp",980,1306]